Endonovo Therapeutics, Inc. revenue by segment ENDV

Annual Quarterly

Endonovo Therapeutics, Inc. splits its revenue into 2 lines in its filings. The largest line in fiscal 2022, which ended Dec 31, 2022 was Royalty at $113,623, 84% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2023 Sep 30, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016	FY 2015 Dec 31, 2015	FY 2014 Dec 31, 2014	FY 2012 Dec 31, 2012
Revenue	0	0	0	0	0	0	—	—	0	0	0
Royalty	—	0 share 83.9%	—	—	—	—	—	—	—	—	—
Direct Sales Medical Care Providers Gross	—	0 -70.3% share 16.1%	0 -55.9% share 100.0%	0 share 100.0%	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as: ENDV (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Woodland Hills, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1528172
Former names: Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)

Other Electromedical & Electrotherapeutic Apparatus companies

All 31 Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.